QuietMIND Foundation is a public non-profit research foundation and an outpatient healthcare practice. We provide neurofeedback therapy within the Great Philadelphia region. Our staff includes internationally recognized, highly-trained, professionals drawn from the fields of biofeedback and neuropsychology, neurophysiology, functional medicine, neuropsychiatry, neuroscience research, organizational consulting, and the law.
We also rely on the skills of staff and professionally trained volunteers to design and deliver our marketing and advertising campaigns, and perform some of our administrative functions. We have a national and worldwide network of professionals we consult with to assist us. We actively train and involve our interns in the fundamental work necessary for developing and conducting applied clinical research projects including writing grant proposals, educational programs and maintaining our library and institutional contacts.
We also rely on the skills of staff and professionally trained volunteers to design and deliver our marketing and advertising campaigns, and perform some of our administrative functions. We have a national and worldwide network of professionals we consult with to assist us. We actively train and involve our interns in the fundamental work necessary for developing and conducting applied clinical research projects including writing grant proposals, educational programs and maintaining our library and institutional contacts.
|
|
Marvin H. Berman, Ph.D., C.B.T.,
Founder & President
Dr. Berman earned his Master’s and PhD in Psychoeducational Processes from Temple University, where he studied group and organizational behavior. He obtained certification in Bioenergetic Analysis at the Philadelphia Institute for Bioenergetic Analysis in 1983. He has participated in post-graduate training workshops and seminars in Systems-Centered Therapy, and the Feldenkrais Method. He was certified in EEG biofeedback in 2003. Dr. Berman currently consults to senior executives and management teams on the application of cognitive neuroscience in leadership development and performance. He has often consulted on issues regarding team development, group relations, and organizational culture. He has taken a leadership role in expanding the application of EEG biofeedback and related technologies into the treatment of and neurodegenerative and neuropsychiatric disorders.
| from_bioenergetics_to_bioenergetics.pdf |
Trent W. Nichols, MD, Chairman, Scientific Advisory Board
Dr. Nichols is a Northwestern Univ. graduate and post-graduate in Neurogastroenterology. He pioneered the development of moderate magnetic field therapy involving zero point and 0.5T magnetic therapy for neurodegenerative disorders. He joined QMF to advance the development of self-administered applications of his pioneering work in noninvasive therapeutics. He has been developing new medications and medical devices for over 50 years as well as now consulting with patients on the effective use of medical marijuana. Dr. Nichols is also the Chief Medical Officer for the International Cancer Association for Education and Research (ICARE).
Paul Chazot, PhD, Scientific Advisory Board Member, Dept. of Biosciences, Durham University, Durham UK.
Dr. Chazot has produced a significant body of research on the mechanisms and clinical application of 1068-1080nm pulsed photobiomodulation. He has been the basic science mentor for QMF and leading advocate for the exploration of PBM as a potential disease-modifying intervention strategy, who with Dr. Gordon Dougal MD, BSEE have been the driving force behind the development of the Cognitolite technology. Quietmind Fdn. was fortunate to be chosen to conduct the first human clinical trials using the 1070nm PBMT device in 2009 and over the next 15 years, now with our study partners at Baylor Research Institute in Temple, TX
Allan Lundy, Ph.D., IRB Chairman
Dr Lundy earned his PhD in Social Psychology from Harvard University in 1981. Between 1992 and 2003 he was on the faculty of the Department of Psychiatry at Jefferson Medical College. During that time, he published 32 articles and book chapters. In his last six years at Jefferson he was Principal Investigator on NIH and other grants totaling over two million dollars. Since 2003 he has been an independent consultant in research methods and statistical analysis.
Jeffrey Leighton, PhD, Director of Neuromodulation Research
Dr. Nichols is a Northwestern Univ. graduate and post-graduate in Neurogastroenterology. He pioneered the development of moderate magnetic field therapy involving zero point and 0.5T magnetic therapy for neurodegenerative disorders. He joined QMF to advance the development of self-administered applications of his pioneering work in noninvasive therapeutics. He has been developing new medications and medical devices for over 50 years as well as now consulting with patients on the effective use of medical marijuana. Dr. Nichols is also the Chief Medical Officer for the International Cancer Association for Education and Research (ICARE).
Paul Chazot, PhD, Scientific Advisory Board Member, Dept. of Biosciences, Durham University, Durham UK.
Dr. Chazot has produced a significant body of research on the mechanisms and clinical application of 1068-1080nm pulsed photobiomodulation. He has been the basic science mentor for QMF and leading advocate for the exploration of PBM as a potential disease-modifying intervention strategy, who with Dr. Gordon Dougal MD, BSEE have been the driving force behind the development of the Cognitolite technology. Quietmind Fdn. was fortunate to be chosen to conduct the first human clinical trials using the 1070nm PBMT device in 2009 and over the next 15 years, now with our study partners at Baylor Research Institute in Temple, TX
Allan Lundy, Ph.D., IRB Chairman
Dr Lundy earned his PhD in Social Psychology from Harvard University in 1981. Between 1992 and 2003 he was on the faculty of the Department of Psychiatry at Jefferson Medical College. During that time, he published 32 articles and book chapters. In his last six years at Jefferson he was Principal Investigator on NIH and other grants totaling over two million dollars. Since 2003 he has been an independent consultant in research methods and statistical analysis.
Jeffrey Leighton, PhD, Director of Neuromodulation Research
